Stock listing

Bionxt Solutions Inc

Selected listing: A3D1K3 · LS · EUR · DE

Bionxt Solutions Inc (Lang & Schwarz: A3D1K3), Health Technology. Latest release Sep 8, 2026: BioNxt Advances Sublingual Everolimus ODF for Organ Transplant…

A3D1K3:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A3D1K3
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Other
Exchange: Lang & Schwarz
Currency: EUR

About Bionxt Solutions Inc

The company focuses on developing innovative solutions in its industry. Bionxt Solutions aims to enhance its market presence and drive growth through its strategic initiatives.

Latest news from Bionxt Solutions Inc

BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study

September 8, 2026

BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants

August 21, 2026

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline

August 4, 2026

BioNxt Solutions Announces Option Grants

July 31, 2026

BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway

July 6, 2026

All Bionxt Solutions Inc news →

Research Bionxt Solutions Inc

Bionxt Solutions Inc company profile

View the public company page for Bionxt Solutions Inc on 6ix.

Bionxt Solutions Inc news

Read company news and market updates connected to Bionxt Solutions Inc.

Bionxt Solutions Inc investor events

Find investor webinars, events, and replay context for Bionxt Solutions Inc.